Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.

Identifieur interne : 002259 ( PubMed/Corpus ); précédent : 002258; suivant : 002260

Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.

Auteurs : Vladimir Zamotin ; Anna Gharibyan ; Natalia V. Gibanova ; Marika A. Lavrikova ; Dmitry A. Dolgikh ; Michail P. Kirpichnikov ; Irina A. Kostanyan ; Ludmilla A. Morozova-Roche

Source :

RBID : pubmed:16638570

English descriptors

Abstract

Prefibrillar cytotoxicity was suggested as a common amyloid characteristic. We showed two types of albebetin prefibrillar oligomers are formed during incubation at pH 7.3. Initial round-shaped oligomers consist of 10-15 molecules determined by atomic force microscopy, do not bind thioflavin-T and do not affect viability of granular neurons and SH-SY5Y cells. They are converted into ca. 30-40-mers possessing cross-beta-sheet and reducing viability of neuronal cells. Neither monomers nor fibrils possess cytotoxicity. We suggest that oligomeric size is important for stabilising cross-beta-sheet core critical for cytotoxicity. As albebetin was used as a carrier-protein for drug delivery, examination of amyloidogenicity is required prior polypeptide biomedical applications.

DOI: 10.1016/j.febslet.2006.03.074
PubMed: 16638570

Links to Exploration step

pubmed:16638570

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.</title>
<author>
<name sortKey="Zamotin, Vladimir" sort="Zamotin, Vladimir" uniqKey="Zamotin V" first="Vladimir" last="Zamotin">Vladimir Zamotin</name>
<affiliation>
<nlm:affiliation>Department of Medical Biochemistry and Biophysics, Umeå University, SE-901 87 Umeå, Sweden.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gharibyan, Anna" sort="Gharibyan, Anna" uniqKey="Gharibyan A" first="Anna" last="Gharibyan">Anna Gharibyan</name>
</author>
<author>
<name sortKey="Gibanova, Natalia V" sort="Gibanova, Natalia V" uniqKey="Gibanova N" first="Natalia V" last="Gibanova">Natalia V. Gibanova</name>
</author>
<author>
<name sortKey="Lavrikova, Marika A" sort="Lavrikova, Marika A" uniqKey="Lavrikova M" first="Marika A" last="Lavrikova">Marika A. Lavrikova</name>
</author>
<author>
<name sortKey="Dolgikh, Dmitry A" sort="Dolgikh, Dmitry A" uniqKey="Dolgikh D" first="Dmitry A" last="Dolgikh">Dmitry A. Dolgikh</name>
</author>
<author>
<name sortKey="Kirpichnikov, Michail P" sort="Kirpichnikov, Michail P" uniqKey="Kirpichnikov M" first="Michail P" last="Kirpichnikov">Michail P. Kirpichnikov</name>
</author>
<author>
<name sortKey="Kostanyan, Irina A" sort="Kostanyan, Irina A" uniqKey="Kostanyan I" first="Irina A" last="Kostanyan">Irina A. Kostanyan</name>
</author>
<author>
<name sortKey="Morozova Roche, Ludmilla A" sort="Morozova Roche, Ludmilla A" uniqKey="Morozova Roche L" first="Ludmilla A" last="Morozova-Roche">Ludmilla A. Morozova-Roche</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16638570</idno>
<idno type="pmid">16638570</idno>
<idno type="doi">10.1016/j.febslet.2006.03.074</idno>
<idno type="wicri:Area/PubMed/Corpus">002259</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002259</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.</title>
<author>
<name sortKey="Zamotin, Vladimir" sort="Zamotin, Vladimir" uniqKey="Zamotin V" first="Vladimir" last="Zamotin">Vladimir Zamotin</name>
<affiliation>
<nlm:affiliation>Department of Medical Biochemistry and Biophysics, Umeå University, SE-901 87 Umeå, Sweden.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gharibyan, Anna" sort="Gharibyan, Anna" uniqKey="Gharibyan A" first="Anna" last="Gharibyan">Anna Gharibyan</name>
</author>
<author>
<name sortKey="Gibanova, Natalia V" sort="Gibanova, Natalia V" uniqKey="Gibanova N" first="Natalia V" last="Gibanova">Natalia V. Gibanova</name>
</author>
<author>
<name sortKey="Lavrikova, Marika A" sort="Lavrikova, Marika A" uniqKey="Lavrikova M" first="Marika A" last="Lavrikova">Marika A. Lavrikova</name>
</author>
<author>
<name sortKey="Dolgikh, Dmitry A" sort="Dolgikh, Dmitry A" uniqKey="Dolgikh D" first="Dmitry A" last="Dolgikh">Dmitry A. Dolgikh</name>
</author>
<author>
<name sortKey="Kirpichnikov, Michail P" sort="Kirpichnikov, Michail P" uniqKey="Kirpichnikov M" first="Michail P" last="Kirpichnikov">Michail P. Kirpichnikov</name>
</author>
<author>
<name sortKey="Kostanyan, Irina A" sort="Kostanyan, Irina A" uniqKey="Kostanyan I" first="Irina A" last="Kostanyan">Irina A. Kostanyan</name>
</author>
<author>
<name sortKey="Morozova Roche, Ludmilla A" sort="Morozova Roche, Ludmilla A" uniqKey="Morozova Roche L" first="Ludmilla A" last="Morozova-Roche">Ludmilla A. Morozova-Roche</name>
</author>
</analytic>
<series>
<title level="j">FEBS letters</title>
<idno type="ISSN">0014-5793</idno>
<imprint>
<date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amyloid (metabolism)</term>
<term>Animals</term>
<term>Biopolymers (chemistry)</term>
<term>Biopolymers (toxicity)</term>
<term>Cells, Cultured</term>
<term>Cerebellum (cytology)</term>
<term>Cerebellum (drug effects)</term>
<term>Cerebellum (metabolism)</term>
<term>Circular Dichroism</term>
<term>Male</term>
<term>Microscopy, Atomic Force</term>
<term>Neurons (drug effects)</term>
<term>Neurons (metabolism)</term>
<term>Proteins (chemistry)</term>
<term>Proteins (toxicity)</term>
<term>Rats</term>
<term>Rats, Wistar</term>
<term>Recombinant Proteins (chemistry)</term>
<term>Recombinant Proteins (toxicity)</term>
<term>Spectrophotometry, Ultraviolet</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Biopolymers</term>
<term>Proteins</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Amyloid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en">
<term>Biopolymers</term>
<term>Proteins</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Cerebellum</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Cerebellum</term>
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Cerebellum</term>
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cells, Cultured</term>
<term>Circular Dichroism</term>
<term>Male</term>
<term>Microscopy, Atomic Force</term>
<term>Rats</term>
<term>Rats, Wistar</term>
<term>Spectrophotometry, Ultraviolet</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Prefibrillar cytotoxicity was suggested as a common amyloid characteristic. We showed two types of albebetin prefibrillar oligomers are formed during incubation at pH 7.3. Initial round-shaped oligomers consist of 10-15 molecules determined by atomic force microscopy, do not bind thioflavin-T and do not affect viability of granular neurons and SH-SY5Y cells. They are converted into ca. 30-40-mers possessing cross-beta-sheet and reducing viability of neuronal cells. Neither monomers nor fibrils possess cytotoxicity. We suggest that oligomeric size is important for stabilising cross-beta-sheet core critical for cytotoxicity. As albebetin was used as a carrier-protein for drug delivery, examination of amyloidogenicity is required prior polypeptide biomedical applications.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">16638570</PMID>
<DateCompleted>
<Year>2006</Year>
<Month>05</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0014-5793</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>580</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2006</Year>
<Month>May</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.</ArticleTitle>
<Pagination>
<MedlinePgn>2451-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Prefibrillar cytotoxicity was suggested as a common amyloid characteristic. We showed two types of albebetin prefibrillar oligomers are formed during incubation at pH 7.3. Initial round-shaped oligomers consist of 10-15 molecules determined by atomic force microscopy, do not bind thioflavin-T and do not affect viability of granular neurons and SH-SY5Y cells. They are converted into ca. 30-40-mers possessing cross-beta-sheet and reducing viability of neuronal cells. Neither monomers nor fibrils possess cytotoxicity. We suggest that oligomeric size is important for stabilising cross-beta-sheet core critical for cytotoxicity. As albebetin was used as a carrier-protein for drug delivery, examination of amyloidogenicity is required prior polypeptide biomedical applications.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zamotin</LastName>
<ForeName>Vladimir</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Biochemistry and Biophysics, Umeå University, SE-901 87 Umeå, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gharibyan</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gibanova</LastName>
<ForeName>Natalia V</ForeName>
<Initials>NV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lavrikova</LastName>
<ForeName>Marika A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dolgikh</LastName>
<ForeName>Dmitry A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kirpichnikov</LastName>
<ForeName>Michail P</ForeName>
<Initials>MP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kostanyan</LastName>
<ForeName>Irina A</ForeName>
<Initials>IA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morozova-Roche</LastName>
<ForeName>Ludmilla A</ForeName>
<Initials>LA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2006</Year>
<Month>04</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000682">Amyloid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001704">Biopolymers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>145185-92-8</RegistryNumber>
<NameOfSubstance UI="C074146">albebetin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001704" MajorTopicYN="N">Biopolymers</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018625" MajorTopicYN="N">Microscopy, Atomic Force</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013056" MajorTopicYN="N">Spectrophotometry, Ultraviolet</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2006</Year>
<Month>02</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2006</Year>
<Month>03</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2006</Year>
<Month>03</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2006</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2006</Year>
<Month>5</Month>
<Day>31</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2006</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">16638570</ArticleId>
<ArticleId IdType="pii">S0014-5793(06)00404-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.febslet.2006.03.074</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002259 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002259 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:16638570
   |texte=   Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:16638570" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021